ANAkinra for the treatment of CORonavirus infectious disease 2019 in the Intensive Care Unit (ANACOR-IC)

COVID-19 is associated with an intense inflammatory response, especially in the sickest patients in Intensive Care. These patients therefore also have more thrombotic complications. Some successful therapies have been found, all of which reduce inflammation, thereby reducing mortality from COVID. However, it is not known whether there are subgroups of patients who respond better or less well to these therapies, or what the effect of these agents is on thrombosis; nor on the specific clotting mechanisms that lead to thrombosis. This project investigated the effect of various interventions on the immune system and the coagulation cascade. Results are important to be able to provide the right therapy to the right patient and to better understand the occurrence of thrombosis during intense inflammatory reactions. More information Read more about research into corona and COVID-19 UMC Utrecht: groundbreaking new treatment for seriously ill corona patients